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Abstract
Background: Matrix metalloproteinases (MMPs) may have pro and antifibrotic roles within the lungs, due to its ability tomodulate
collagen turnover and immune mediators. MMP-8 is a collagenase that also cleaves a number of cytokines and chemokines.
Methodology and Principal Findings: To evaluate its relevance in lung fibrosis, wildtype and Mmp82/2 mice were treated
with either intratracheal bleomycin or saline, and lungs were harvested at different time points. Fibrosis, collagen,
collagenases, gelatinases, TGFb and IL-10 were measured in lung tissue. Mmp82/2 mice developed less fibrosis than their
wildtype counterparts. This was related to an increase in lung inflammatory cells, MMP-9 and IL-10 levels in these mutant
animals. In vitro experiments showed that MMP-8 cleaves murine and human IL-10, and tissue from knockout animals
showed decreased IL-10 processing. Additionally, lung fibroblasts from these mice were cultured in the presence of
bleomycin and collagen, IL-10 and STAT3 activation (downstream signal in response to IL-10) measured by western blotting.
In cell cultures, bleomycin increased collagen synthesis only in wildtype mice. Fibroblasts from knockout mice did not show
increased collagen synthesis, but increased levels of unprocessed IL-10 and STAT3 phosphorylation. Blockade of IL-10
reverted this phenotype, increasing collagen in cultures.
Conclusions: According to these results, we conclude that the absence of MMP-8 has an antifibrotic effect by increasing IL-
10 and propose that this metalloprotease could be a relevant modulator of IL-10 metabolism in vivo.
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Introduction
The accumulation of collagen fibers in the lung interstitium is a
form of abnormal repair in some respiratory diseases. The primary
forms of this syndrome are largely unknown and grouped under
the term idiopathic pulmonary fibrosis [1]. Lung fibrosis can be
also secondary to different types of injury, such as persistent acute
respiratory distress syndrome, asbestos or silica exposure or
treatment with drugs such as bleomycin [2]. Chronic inflamma-
tion is one of the mechanisms leading to these diseases. This is
especially relevant in secondary fibrosis, but its involvement in the
idiopathic forms is discussed [3]. The clinical course of this
pathology shows a poor response to different therapies including
steroids and other immuno-suppressors, and often evolves to
irreversible respiratory failure [4].
Matrix metalloproteinases (MMPs) are a family of enzymes
involved in different processes such as modulation of inflammation,
tissue remodeling and collagen processing [5]. These enzymes play
an important role in the pathogenesis of pulmonary fibrosis [6]. By
targeting different substrates and being controlled by diverse
regulatory mechanisms [7], MMPs establish a complex network
in which different enzymes may play opposite roles. Likewise,
specific family members may also play different roles in different
time points of the disease. This is the case forMMP-8, also known as
collagenase-2. This enzyme can digest native collagen, but its
function in vivo seems to be more related to the control of the
inflammatory response [8,9]. By the ability to cleave different
cytokines and chemokines, MMP-8 promotes the initial onset and
the later clearance of the neutrophilic inflammatory response. Mice
lacking MMP-8 show a delayed wound healing due to a persistent
inflammatory infiltrate [10]. Additionally, it has been observed a
decreased collagen deposition in the wounds of these animals. This
abnormal response could be of interest within the lungs challenged
with a profibrotic stimulus. Therefore, we hypothesized that mice
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lacking MMP-8 would develop less lung fibrosis than their
respective wildtype counterparts. To test this hypothesis, we used
a widely known model of lung fibrosis based on the administration
of intratracheal bleomycin [11]. This drug induces an acute
inflammatory response followed by the development of fibrosis,
allowing to study the putative role of MMP-8 by assessing the
differences between wildtype andMmp8 knockout mice after injury.
Results
Lung fibrosis is decreased in Mmp82/2 mice
Lung fibrosis was quantified using the Ashcroft scale in
histological sections stained with Masson’s trichrome (Figure 1A).
No sign of fibrosis was detected in saline-treated mice of either
genotype. Bleomycin injection induced a fibrotic response after 3
weeks. However, the degree of fibrosis was lower in MMP-8
deficient animals, as mutant mice scores were significantly lower
than their wildtype counterparts (p,0.05 in post-hoc pairwise
comparisons). After 6 weeks, fibrosis persisted in wildtype mice, but
was partially solved in mutant animals. Consistent with this finding,
there was a peak in recently synthesized collagen (Figure 1B) only in
wildtype mice 3 weeks after bleomycin injection. Knockout mice
showed a non-significant increase in this parameter (Figure 1B).
Representative histological preparations are shown in Figure 2.
Bronchiolization appeared only after bleomycin administration,
and not in saline-treated mice and increased progressively up to 6
weeks after injury. There were no differences between genotypes
(data not shown).
Changes in collagenolytic and gelationlytic activities after
bleomycin treatment
Collagenases and gelatinases act sequentially to degrade collagen.
To study the implication of MMP-8 in the pathogenesis of
bleomycin-induced fibrosis we measured its level in lung homog-
enates (Figure 3A). This enzyme increased 3 days after bleomycin
instillation, to decrease later. Of note, saline-treated mice showed a
modest increase in this enzyme, suggesting that the instillation
procedure can induce a minor inflammatory response within the
lungs. As expected, MMP-8 was not detected in knockout mice.
Then, we focused on differences in other collagenases and
gelatinases to discard compensatory mechanisms in mutant mice.
First, we assessed collagenolytic activity of lung homogenates (3
days and 3 weeks after bleomycin treatment). There were no
differences in total collagenolytic activity between wildtype and
knockout mice, thus discarding an overcompensatory increase of
other collagenolytic enzymes in Mmp82/2 mice that could explain
the decreased fibrosis (Figure 3B–C).
Regarding gelatinases, knockout mice showed a significant
increase in MMP-9 in lung homogenates when studied 3 days after
bleomycin instillation (Figure 3D). Values returned to baseline levels
at the other time points of the study. In contrast, wildtype mice
showed only a small increase that did not reach statistical
significance. MMP-2 (Figure 3D) is another gelatinase involved in
the pathogenesis of lung fibrosis [12]. We observed an increase in
this enzyme in both wildtype and knockout mice 3 weeks after
injury. There were no changes in any gelatinase in saline-treated
animals. MMP-8 (Figure 3G) was expressed mainly in fibroblasts,
whereas MMP-9 expression was restricted to inflammatory cells,
mainly neutrophils, as shown by immunohistochemistry (Figure 3H).
Increased inflammatory infiltrate in Mmp82/2 mice
Bleomycin causes an acute inflammatory response within the
lungs, which was measured by quantifying myeloperoxidase
activity in tissue extracts. Myeloperoxidase (Figure 4A) increased
in both wildtype and knockout mice 3 days after bleomycin
injection, but not after saline. Noteworthy, that increase was more
pronounced in knockout mice, as demonstrated by immunohisto-
chemical analysis showing higher counts of myeloperoxidase-
positive cells (Figure 4B–D). In mutant animals, increased levels of
myeloperoxidase persisted along the 6 weeks of the experiment,
whereas returned to baseline levels in wildtype mice.
Th2 cytokines TGFb and IL-10 are differentially regulated
in Mmp82/2 mice
Th2 cytokines could play a relevant role in the development of
fibrosis after bleomycin instillation. TGFb is a profibrogenic factor
that increased 3 and 6 weeks after bleomycin treatment only in
Figure 1. Decreased fibrosis in mice lacking MMP-8 challenged
with intratracheal bleomycin. Fibrosis was quantified using the
Ashcroft score (A) and recently synthesized collagen (B) measured in
lung homogenates (n$6 per group). 1,2,3P,0.05 in post-hoc test when
compared against 3 days (1), 3 weeks (2) or 6 weeks (3) within the same
genotype and treatment; *p,0.05 when compared against wildtype
within the same time and treatment; #p,0.05 when compared against
saline within the same time and genotype.
doi:10.1371/journal.pone.0013242.g001
Lung Fibrosis in Mmp82/2 Mice
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wildtype mice. In contrast,Mmp8-deficient mice showed lower levels
of this cytokine in the early phase (3 days) and values comparable to
saline-treated mice at the other time points (Figure 5A).
IL-10 is another anti-inflammatory cytokine that can suppress
TGFb synthesis, thus exerting antifibrotic effects. There were no
changes in this cytokine in saline-treated mice of both genotypes, or
in bleomycin-treated wildtype animals. However, Mmp82/2 mice
showed a 3-fold increase in IL-10 3 weeks after bleomycin
treatment, and a smaller but still significant increase persisted 6
weeks after injury (Figure 5B). Immunohistochemical studies
demonstrated IL-10 expression in epithelial cells and fibroblasts,
whereas MMP-8 was expressed in fibroblasts (Figure 5C). When IL-
10 gene expression was studied, mRNA levels of this cytokine in
baseline conditions were undetectable. However, they were
detected 3 days after bleomycin instillation with no differences
between genotypes. Interestingly, IL-10 mRNA decreased signifi-
cantly in knockout mice 3 weeks after bleomycin (Figure 5D). These
findings open the possibility that IL-10 could be responsible for the
benefits seen in terms of fibrosis in knockout mice and suggests that
MMP-8 can be a relevant modulator of IL-10 function.
MMP-8 processes IL-10 in vitro and in vivo
To explore the possibility that IL-10 could be a substrate of
MMP-8, recombinant murine IL-10 was incubated with this
Figure 2. Representative histological sections (206) from each experimental group. After staining with Masson’s trichrome, fibrosis
appears as green fibers, whereas epithelial and inflammatory cells are stained in red.
doi:10.1371/journal.pone.0013242.g002
Lung Fibrosis in Mmp82/2 Mice
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enzyme. After 18 hours of incubation, proteolytic processing of the
cytokine was demonstrated by western blotting, showing that IL-
10 (18 kDa) was converted to lower molecular mass species
(,14 kDa). The appearance of these species was inhibited by
TIMP-1 (Figure 6A). We repeated this experiment using
recombinant human IL-10, showing the same result (Figure 6B).
In vivo processing of IL-10 by MMP-8 was studied in lung
tissue homogenates by western blotting using a polyclonal
antibody against mouse IL-10. Two IL-10 positive bands were
detected at 18 and 14 kDa, corresponding to intact and
processed IL-10 (Figure 6C). The percentage of intact IL-10
was higher in knockout mice three days and three weeks after
bleomycin instillation (Figure 6D), demonstrating that absence of
MMP-8 results in higher levels of unprocessed IL-10 and,
therefore, that MMP-8 is an important regulator of IL-10
function in vivo.
Antifibrotic response in Mmp82/2 fibroblasts is IL-10
dependent
The relationship between IL-10 processing and lung fibrosis
suggested by the above experiments was demonstrated in a culture
model. Lung fibroblasts from wildtype and mutant mice were
treated with bleomycin. After bleomycin challenge, there was an
increase in IL-10 processing in wildtype fibroblasts, and intact IL-
10 (18 kD) was significantly decreased. However, there was no
change in IL-10 processing in cultures from knockout mice
(Figure 7A–B). We also studied STAT3 phosphorylation as a
marker of IL-10 activity. The ratio of phosphorylated to non-
Figure 3. MMP activity in each experimental group. A: MMP-8 increased after bleomycin instillation. As expected, no MMP-8 was detected in
knockout mice (n$7 per group). B–C: Collagenolytic activity of lung tissue homogenates from wildtype and knockout mice 3 days (B) and 3 weeks (C)
after bleomycin instillation (n = 3 per group). There are no significant differences between genotypes. D: MMP-9 has an acute increase after
bleomycin instillation only in knockout mice (n$7 per group). E: MMP-2 increases in both wildtype and knockout mice 3 weeks after injury (n$7 per
group). F: Representative western blotting and gelatin zymography used to quantify these MMPs. G–H: Immunohistochemical staining of MMP-8 (G)
and MMP-9 (H) after bleomycin instillation. 1,2,3p,0.05 in post-hoc test when compared against 3 days (1), 3 weeks (2), 6 weeks (3) within the same
genotype and treatment; *p,0.05 when compared against wildtype within the same time and treatment; #p,0.05 when compared against saline
within the same time and genotype.
doi:10.1371/journal.pone.0013242.g003
Lung Fibrosis in Mmp82/2 Mice
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phosphorylated STAT3 was markedly increased in cultures from
knockout mice in the presence of bleomycin. This increase was
significantly attenuated when a blocking anti-IL10 antibody was
added to the medium, thus demonstrating that it was caused by an
increase in bioactive IL-10 (Figure 7C) and therefore suggesting
that the cleaved form of IL-10 has a decreased activity. In
agreement with the results observed in mice, collagen increased
after bleomycin treatment in cell cultures from Mmp8+/+ mice but
not from Mmp82/2 animals. The addition of an IL-10 blocking
antibody increased collagen levels in cultures from Mmp82/2 mice
up to those seen in their wildtype counterparts (Figure 7D). These
results demonstrate that the decreased fibrosis seen in mutant mice
is caused directly by the increase in IL-10. There were no
differences in IL-10 receptor expression (Figure 7E). Representa-
tive western blots of these experiments are shown in Figure 7E.
Discussion
Our results demonstrate that absence of MMP-8 results in an anti-
fibrotic effect after bleomycin administration. This effect is mediated
by the absence of proteolytic cleavage and subsequent inactivation of
endogenous IL-10. Collectively, these results demonstrate thatMMP-
8 is an important regulator of IL-10 in vivo and point this
metalloprotease as a potential therapeutic target in lung fibrosis.
Matrix metalloproteinases have been involved in different
phenomena that occur during inflammation and tissue repair,
such as modulation of the immune response, extracellular matrix
turnover or cell migration [13,14]. There is clear evidence that
MMPs play a key role in lung fibrosis [6,15], although different
enzymes may have opposite effects. For instance, it has been
documented that mice lacking MMP-7 are protected from
bleomycin-induced fibrosis [16]. In contrast, overexpression of
MMP-9 protects against lung fibrosis [17] and absence of this
gelatinase resulted in decreased bronchiolization but no differences
in fibrosis [18]. This variety of effects highlights the need of specific
inhibitors for a clinical application of the experimental findings
[19].
The decreased collagen levels in mice lacking a collagenase
suggested that the benefits seen in these animals were not related
to the effects of MMP-8 on the extracellular matrix proteins.
Moreover, our results show no overcompensatory increase in other
collagenases, and even a slightly decreased collagenolytic activity
in knockout mice. As the Sircol assay only measures newly
synthesized collagen, and not covalent cross-linked fibers, the
lower levels of collagen seen in mutant animals suggest a decreased
rate of synthesis. This can also explain the absence of differences in
soluble collagen seen after 6-weeks in spite of a marked difference
in histological scores.
Therefore, we focused on mechanisms other than collagen
degradation. MMP-8 has some interesting effects in acute and
chronic inflammation. Animals lacking this enzyme have a delayed
onset of the acute inflammatory response in different experimental
Figure 4. Increased inflammatory infiltrate activity in Mmp82/2 mice treated with bleomycin. A: Myeloperoxidase was considered a
surrogate marker of neutrophilic infiltration of lung tissue (n$7 per group). B: The number of myeloperoxidase-positive cells was higher in knockout
mice. C–D: Representative immunohistochemistry for myeloperoxidase in wildtype (C) and knockout (D) animals. 1,2,3P,0.05 in post-hoc test when
compared against 3 days (1), 3 weeks (2), 6 weeks (3) within the same genotype and treatment; *p,0.05 when compared against wildtype within the
same time and treatment; #p,0.05 when compared against saline within the same time and genotype.
doi:10.1371/journal.pone.0013242.g004
Lung Fibrosis in Mmp82/2 Mice
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models [8,10,20]. However, once established, the inflammatory
infiltrate persists for longer times than in controls. Moreover,
MMP-8 may also regulate lung permeability [21], which is an
important determinant of outcome in pulmonary fibrosis [22], and
apoptosis of inflammatory cells [23]. It has been proposed that
MMP-8 is a master regulator of neutrophil chemotaxis by cleavage
of chemokines such as MIP-1a [24] or LIX [9], the murine
ortologue of human IL-8. This increased inflammation after
bleomycin instillation has been recently described in detail [24].
Based on these results, the decreased fibrosis seen in or mice
cannot be explained by lower levels of acute damage, as lung
injury at 7 days after bleomycin instillation is even higher in
mutant animals.
A collateral effect of this delayed clearance of inflammation in a
model of skin wounds was a decreased collagen deposition and
therefore a delayed healing [10]. Our results follow the same
pattern, but in this case the decreased fibrosis is beneficial rather
than a side effect. In contrast to the findings in MMP-9 deficient
mice [18], we did not observe differences in bronchiolization.
Many of the results seen in disease models using mice lacking
MMPs are due to differences in cytokine and chemokine
processing. Cleavage of these immune mediators by MMPs can
modulate their activity [25]. Different cytokines are involved in the
pathogenesis of pulmonary fibrosis. TGFb is the most important
profibrotic mediator [26]. This cytokine has also an anti-
inflammatory effect. Of note, the pattern of increased inflamma-
tion and decreased fibrosis after bleomycin instillation has been
observed in mice lacking the integrin avb6, which is an activator of
latent TGFb [27].
Another cytokine involved in the regulation of the inflammatory
response, fibrosis and TGFb regulation is IL-10. We found an
increase in this cytokine in mice lacking MMP-8 submitted to
ventilator-induced lung injury [28]. Moreover, it has been
published that interleukin-10 can exert antifibrotic effects after
bleomycin instillation. Arai and coworkers [29] demonstrated that
overexpression of IL-10 reduced fibrosis in vivo. Similar results
were found by Nakagome et al [30], who showed in bleomycin-
injected mice that IL-10 decreased TGFb expression in the lung,
Figure 5. Cytokines in lung homogenates. A: TGFb increases after bleomycin-induced lung injury only in wildtype mice, whereas knockout mice
show lower level in all the stages of the experiment. B: IL-10 increases in knockout mice during the chronic phase. N$5 per group. C:
Immunohistochemistry for IL-10 and MMP-8 in lungs from wildtype mice after bleomycin instillation, showing IL-10 expression in epithelium and
fibroblasts within the alveolar septa. MMP-8 was expressed in fibroblasts. D: IL-10 expression after bleomycin instillation shows no differences
between genotypes after 3 days, and a significant decrease in IL-10 mRNA in knockout mice 3 weeks after instillation. 1,2,3P,0.05 in post-hoc test
when compared against 3 days (1), 3 weeks (2), 6 weeks (3) within the same genotype and treatment; *p,0.05 when compared against wildtype
within the same time and treatment; #p,0.05 when compared against saline within the same time and genotype.
doi:10.1371/journal.pone.0013242.g005
Lung Fibrosis in Mmp82/2 Mice
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especially in macrophages. Part of the inhibitory effect of IL-10 on
TGFb is caused by a decreased expression of integrin avb6.
However, this cannot be the only mechanism responsible for
decreased TGF in knockout mice, as these animals show lower
levels even before the increase in IL-10 (i.e. 3 days after
bleomycin). Although it has been reported that Mmp82/2 mice
have a defective TGFb signaling pathway, the underlying
mechanisms are not completely elucidated [10].
Similar results were found using a model of fibrosis associated
with chronically inhaled endotoxin [31]. However, there are also
reports of a profibrotic role of IL-10 in lung fibrosis induced by
silica [32]. Differences in injury model could have been
responsible for the discrepancies.
We have shown here that IL-10 is inactivated by MMP-8. This
result is reinforced by the absence of differences in IL-10
expression, and even by the decrease in IL-10 expression
coinciding with the peak of protein levels. It has been published
that IL-10 exerts a paracrine negative feedback involving its own
receptors [33]. Moreover, the culture model suggests that the
antifibrotic effect seen in our mutant mice is IL-10-dependent.
Using IL-10 deficient animals, Kradin and coworkers have not
found a difference in lung fibrosis [34]. This is in agreement with
our findings, as one can expect that released IL-10 in wildtype
mice is inactivated by MMP-8. Collectively, our results are
consistent with a model in which absence of MMP-8 results in
increased inflammation, but also increased levels of IL-10.
Recruited neutrophils release MMP-9, which has a protective
role in bleomycin-induced fibrosis [17] through cleavage of
potential profibrotic mediators such as insulin-like growth factor
binding protein-3 (IGFBP3). Simultaneously, intact IL-10, either
directly or by decreasing TGFb [30], ameliorates the fibrotic
process, therefore leading to the beneficial effects seen in knockout
mice. This mechanism is depicted in figure 8.
Based on these findings, MMP-8 could be a therapeutic target in
lung fibrosis. For this strategy to be effective, selective inhibitors should
be used to avoid interference with other MMPs with antifibrotic
properties. However, this therapeutic approach should be viewed with
caution by different reasons: First, the increased inflammatory
response seen in absence of MMP-8 could be detrimental and
promote additional injury. Although there was no increased lung
damage inMmp82/2mice, and the role of inflammation in idiopathic
fibrosis is discussed, this could be a relevant side effect. Second, the
bleomycin model is not fully representative of the human disease,
neither idiopathic nor secondary [11].
Another implication of our results is that MMP-8 is an
important regulator if IL-10 activity in vivo. This anti-inflamma-
tory cytokine has been proposed as a therapeutic agent in
inflammatory and autoimmune diseases [35]. In these cases, the
possibility of targeting MMP-8 to increase the levels of active IL-
10 could be considered.
In conclusion, we have demonstrated that absence of MMP-8
has an antifibrotic effect mainly driven by an increase in IL-10.
Therefore, selective inhibition of this enzyme could be a
therapeutic approach in pulmonary fibrosis. Our findings illustrate
how this MMP plays a key role in the regulation of the
inflammatory response and the subsequent repair. Moreover, they
open the possibility to modulate IL-10 metabolism by MMP-8
targeting in a variety of diseases.
Figure 6. In vitro cleavage of IL-10. MMP-8 processing of murine (A) and human (B) IL-10 in vitro. Cleavage results in a 14 kDa fragment in
addition to intact IL-10 (18 kDa). In vivo cleavage (C) also occurs. Although there is a 14 kDa fragment in both genotypes, indicating overlapping of
other proteases, the percentage of intact IL-10 is significantly higher (*p,0.05) in knockout mice (D), demonstrating the relevance of MMP-8 in IL-10
metabolism in vivo.
doi:10.1371/journal.pone.0013242.g006
Lung Fibrosis in Mmp82/2 Mice
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Methods
Animals
Eight-week-old male wildtype and Mmp82/2 mice generated in
a mixed C57/Sv129 background [8] were used. Genotypes were
confirmed by PCR. The Animal Research Committee of the
Universidad de Oviedo authorized the experimental protocol.
Experimental design
Mice of both genotypes were randomly assigned to bleomycin or
saline administration. Under anesthesia using vaporized fluorane,
a midline neck incision was done and the trachea exposed. Either
bleomycin (2 units/Kg) or isotonic saline were administered
intratracheally using a 28G needle. After this, the skin was sutured
and the animals left to recover. Four mice (1 saline-treated
Mmp82/2, 1 bleomycin-treated Mmp82/2 and 2 bleomycin-
treated Mmp8+/+) died within the first 5 days after instillation and
were replaced. There were no deaths after this time point. Mice
were sacrificed 3 days, 3 weeks or 6 weeks after the intratracheal
instillation. This results in 12 different groups, depending on the
genotype, treatment and time course after the injury. We included
8-10 animals per group (total 106 mice).
Histological analysis
The left lung was fixated using formaldehyde. Three lung slices,
stained with Masson’s trichrome, were studied. Lung fibrosis was
scored from 0 (no fibrosis) to 8 (massive fibrosis in all fields) using
the Ashcroft scale [36]. Bronchiolozation (presence of bronchial-
like cells in the alveoli) was quantified using the Jensen-Taubman
scale [37]. A pathologist (AA), blinded to genotypes and
experimental conditions, made all the evaluations.
Figure 7. Biological activity of IL-10. The effects of MMP-8 on IL-10 activity were studied in cultured lung fibroblasts from wildtype and knockout
mice (n = 4 per group). Intact IL-10 decreased in wildtype cells cultured in presence of bleomycin (Representative western blot: A; quantification: B).
This was related to a decrease in phosphorylated STAT3 (C), demonstrating a decrease in the activity of IL-10 signaling pathway, and an increase in
Type I collagen (D). In contrast, fibroblasts from knockout mice showed no IL-10 cleavage (A–B), an increase in STAT3 phosphorylation (C) and
decreased collagen synthesis (D). Addition of a neutralizing antibody against IL-10 decreased STAT3 activation and increased collagen. Addition of a
control IgG had no effects. Panel E shows representative western blots of these experiments. *p,0.05 compared against wildtype under the same
culture conditions.
doi:10.1371/journal.pone.0013242.g007
Figure 8. Schematic representation of the mechanisms by
which absence of MMP-8 ameliorates lung fibrosis. In normal
mice (left), presence of MMP-8 facilitates the resolution of inflammation,
thus decreasing MMP-9 (by the clearance of neutrophils) and IL-10 (by
cleavage). The increased TGFb promotes fibrosis. In absence of MMP-8
(right), there are increased levels of MMP-9 and IL-10, both of them with
antifibrotic properties. IL-10 can also inhibit TGFb synthesis. For further
details, see text.
doi:10.1371/journal.pone.0013242.g008
Lung Fibrosis in Mmp82/2 Mice
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To evaluate the inflammatory infiltrate within the lungs,
immunohistochemical analysis was done in sections from bleomy-
cin-treated mice of both genotypes using an anti-myeloperoxidase
antibody (Thermo Fisher Scientific, USA). The number of positive
cells in three microscopic fields (620) was counted and averaged.
Immunostaining in lung sections was done using antibodies against
MMP-8 and IL-10 (Abcam, UK) and MMP-9 (Santa Cruz
Biotechnologies, USA).
Collagen content
Soluble lung collagen was measured in lung homogenates using
the Sircol assay (Biocolor, UK), following manufacturer’s instruc-
tions. Briefly, lung tissue homogenates were mixed with the Sircol
dye and centrifugated. The pellet was resuspended in NaOH and
the optical density at 540 nm measured. The obtained absorbance
is proportional to the abundance of recently synthesized collagen.
Quantification of MMP-8 by western blot
The levels of MMP-8 in lung tissue were measured by western
blotting. Lung homogenates were resolved in a 8% SDS-
polyacrilamide gel, transferred to a nitrocellulose membrane and
incubated with a polyclonal antibody raised in rabbits against
murine MMP-8. A secondary peroxidase-linked anti-rabbit
antibody was used to detect MMP-8 by chemoluminescence, as
previously described. Membranes were scanned in a LAS-3000
camera (Fujifilm, Germany), and intensity of the bands measured
using the ImageJ software.
Collagenolytic activity
Total collagenolytic activity was quantified in lung homogenates
using the EnzChek collagenase assay kit (Invitrogen, USA). Briefly,
fluorescein-conjugate collagen (DQ collagen, Invitrogen, USA)
and tissue homogenates (100 micrograms of total protein) were
incubated at 37uC in a reaction buffer. The increase in
fluorescence, measured at 0.5, 1, 3 and 5 hours, is proportional
to collagenolytic activity of the tissue.
Gelatin zymography
MMP-2 and MMP-9 were measured in lung homogenates using
gelatin zymography. Protein content was adjusted to 20 micro-
grams in all samples, and loaded in a SDS-polyacrylamide gel
containing gelatin, electrophoresed and incubated overnight in an
buffer (150mM NaCl, 5mM CaCl2, 50mM Tris-HCl, pH 7.6).
After staining with Coomassie Blue, gelatinolytic activity appears
as white bands in a blue background. The gels were scanned and
quantified using ImageJ software (National Institutes of Health,
USA).
Myeloperoxidase assay
Myeloperoxidase activity was measured as a marker of
neutrophil infiltration. A lung fragment was homogenated in
phosphate buffer containing CTAB. Tissue homogenates were
incubated with O-dianisidine and H2O2 and light absorbance at
460 nm was measured as a marker of myeloperoxidase content.
Cytokine measurements
Total IL-10 and active TGFb were measured in lung
homogenates using commercial ELISA kits (eBioscience, UK),
following manufacturers’ instructions. Additionally, IL-10 expres-
sion was measured by quantitative PCR. Total lung RNA was
extracted from mouse lungs using TRIzol reagent (Invitrogen Life
Technologies,USA) and reversed transcribed into cDNA (Advan-
tage RT-for-PCR Kit; Clontech, USA). Quantitative reverse
transcription-PCR was carried out in duplicate for each sample
using 20 ng of cDNA, TaqMan Universal PCR master mix and
1 mL of the specific TaqMan custom gene expression assay for
IL10 (Mm01288386_m1, Applied Biosystems, USA). To quantify
gene expression, PCR was performed at 95uC for 10 min,
followed by 40 cycles at 95uC for 15 s, 60uC for 30 s, and 72uC
for 30 s using an ABI Prism 7700 sequence detector system. Gene
expression was normalized to b-actin as control. Relative
expression of the analyzed genes was calculated according to
manufacturer’s instructions.
IL-10 digestion
To assess enzymatic processing of IL-10 by MMP-8, murine or
human IL-10 were incubated with MMP-8 pre-activated with
APMA, at 37uC in a buffer containing 150 mM NaCl, 5 mM
CaCl2, 50 mM Tris-HCl (pH 7.6). Experiments without MMP-8
or adding TIMP-1 to the incubation buffer were conducted in
parallel. After incubation, the samples were resolved by 15% SDS-
PAGE. The proteins were transferred to a nitrocellulose
membrane and detected by western blotting as described before,
using polyclonal anti-mouse or anti-human IL-10 antibodies
(purchased from Abcam, UK and R&D Systems, USA, respec-
tively). To clarify the in vivo relevance of the cleavage of IL-10 by
MMP-8, we detected the cytokine in lung tissue homogenates from
wildtype and knockout mice 3 weeks after bleomycin administra-
tion. IL-10 was detected by western blotting using the same
polyclonal antibody after 15% SDS-PAGE. Bands of different
molecular weight were detected, the intensity of each one was
quantified using ImageJ software. The percentage of unprocessed
IL-10 with respect to the total amount was computed for each
sample.
IL-10 activity assay in cell cultures
Fibroblast cultures were initiated from lung explants from WT
and MMP8 deficient mice as described [38]. Lungs were washed
with PBS, and triturated with razor blades. The disrupted explants
were allowed to adhere to the bottom of the culture plates before
covering them with DMEM cell culture medium supplemented
with penicillin/streptomycin/gentamicin, 10% FBS, nonessential
amino acids (0.1 mM), sodium pyruvate (1 mM), L-glutamine
(2 mM) and N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid
(HEPES) (10 mM). Cultures were maintained at 37uC and 5%
CO2. After the first 2 weeks of culture, most nonfibroblast cells
died while the fibroblasts established as the predominant cell type.
Then, cultured cells were trypsinized, filtered, and washed.
Fibroblasts were seeded in 12-well plates with DMEM without
FBS under the following conditions: Baseline, bleomycin (bleo-
mycin 100 nM), bleomycin plus IL-10 blockade (bleomycin
100 nM and anti-IL10 blocking antibody purchased from
Peprotech Inc) and bleomycin plus unspecific IgG (Abcam, UK).
After 12 hours, supernatants were removed and cell extracts
obtained using a RIPA buffer (100 mM TRIS pH 7.4, 150 mM
NaCl, 10 mM EDTA, 1% deoxycolic acid, 1% Triton X-100,
0.1% SDS, 50 mM NaF, 1 mM orthovanadate and protease
inhibitor cocktail) and stored at 280uC. In these extracts, western
blots were done to measure type I collagen (using an antibody
purchased from Calbiochem, Merck, UK), IL-10 and IL-10
receptor (IL-10RA antibody, Abcam, UK). To measure IL-10
activity, we quantified the phosphorylation balance of the
transcription factor STAT-3 by western blot using antibodies
against phosphorylated and non-phosphorylated forms of STAT3
(Signalway Antibody Co, USA). As loading control we used a
polyclonal anti-actin antibody purchased from Santa Cruz
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Biotechnology Inc (USA). Detection and quantification of the
bands was done as previously described.
Statistical analysis
Results are expressed as mean6SEM. Variables were compared
using an ANOVA, including genotype, treatment and time of
study as factors. When appropriate, post-hoc tests were done using
Bonferroni’s correction. Comparisons between two variables were
done using a T test. A p value lower than 0.05 was considered
significant.
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